



Supplementary Figure 3. miR-151-5p inhibitor regulated human BMMSC lineage differentiation. (A) qPCR analysis showing the levels of miR-151-5p in vehicle- and miR-151-5p inhibitor-treated human BMMSCs (hMSCs). (B) qPCR analysis showing the expression levels of *Il4ra* in vehicle- and miR-151-5p inhibitor-treated hMSCs. (C) Alizarin red staining showing formation of mineralized nodules in of vehicle- and miR-151-5p inhibitor-treated hMSCs under osteoinductive conditions. (D) Western blotting analysis showing the expression levels of the osteogenic genes *RUNX2*, *ALP* and *OCN* in vehicle- and miR-151-5p inhibitor-treated hMSCs. β -Actin was used as a protein loading control. (E) The number of Oil red O⁺ cells in vehicle and miR-151-5p inhibitor-treated hMSCs under adipogenic conditions. (F) The expression levels of adipogenic genes *PPAR γ 2* and *LPL* in vehicle- and miR-151-5p inhibitor-treated hMSCs under adipogenic conditions. All experimental data were verified in at least 3 independent experiments. Error bars represent the s.d. from the mean values. *** $P < 0.005$; ** $P < 0.001$; * $P < 0.05$.